<a href="https://www.fiercebiotech.com/biotech/jj-makes-1b-upfront-bet-emerging-dac-space-netting-firefly-bio" hreflang="en">J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio</a>
Johnson & Johnson has acquired Firefly Bio for $1 billion to enhance its oncology pipeline with a novel degrader antibody conjugate (DAC) platform, aiming to target "undruggable" KRAS-driven tumors. This move reflects a growing interest in DACs among major pharmaceutical companies, as they seek to develop more effective cancer treatments.
Johnson & Johnson's $1 billion acquisition of Firefly Bio highlights the growing strategic interest in degrader antibody conjugates (DACs), a novel platform that merges antibody-drug conjugates with targeted protein degraders to tackle "undruggable" targets like KRAS-driven tumors. This move signals a significant opportunity in expanding oncology pipelines using DACs, suggesting potential for further investments in companies with robust, innovative DAC platforms that address unmet needs in cancer treatment.